The story of Viagra presents a intricate picture for investors. While the initial introduction generated massive gains, the end of its exclusive rights opened the avenue to cheaper alternatives, dramatically reducing sales. This creates a specific challenge for firms relying on comparable blockbuster medications, suggesting that a careless investme

The legacy of Viagra, and its creator copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in income, its intellectual property lapse created a flood of generic competition , significantly impacting its market share . While some pharmaceutical companies may attempt to capitalize on similar conditio